LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against The Hain Celestial Group, Inc. (“Hain” or the “Company”) (NASDAQ: HAIN) concerning possible violations of federal securities laws between November 9, 2015 and August 15, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 17, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, during the Class Period, the Company made false and misleading statements and/or failed to disclose: that Hain lacked effective internal control over financial reporting; that the Company failed to properly account for revenue associated with concessions that were granted to certain distributors in the United States; and a result of the above, Hain’s statements about its business, operations and prospects, were false and misleading and/or lacked a reasonable basis. When this news was announced to the public, shares of Hain decreased in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444496

LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Global Digital Solutions Inc. (“Global Digital” or the “Company”) (Other OTC: GDSI) concerning possible violations of federal securities laws between October 8, 2013 and August 12, 2016 (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 24,
2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, Global Digital made false and misleading statements and/or failed to disclose that: Airtronic USA, Inc.’s original equipment manufacturer supplier agreement that Global Digital disclosed in its October 2013 press releases did not exist; that the Company failed to remove misleading statements from its website even after repeated requests to do so from the CEO of Airtronic; that Global Digital lacked a reasonable basis for its revenue projection for 2014; that the Company had no credible financing to acquire any company; that Global Digital received various communications indicating Remington Outdoor Company, Inc. had no interest in Global Digital’s unsolicited acquisition offer; that Remington had already rejected Global Digital’s offer on several occasions; and that as a result of the above, the Company’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this information was announced, Global Digital shares dropped in value.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444495

TORONTO, ON / ACCESSWIRE / August 29, 2016 / Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the six-month period ended June 30, 2016, total revenue increased from $677,817 to $893,138 from the same period in 2015, an 32% increase.

In Canada, revenue decreased 12% to $497,378 from $562,890, in the US, revenue increased 219% to $316,756 from $99,343 and international revenue increased 407% to $79,004 from $15,584. The decrease in Canadian revenue in 2H2016 and the corresponding increase in US and international revenue is attributable to the Company systematically building its sales and marketing teams in the Canadian and US market and the learning curves associated with training and developing a new sales force.

Now that the TLC-2000 is FDA 510(k) cleared and Health Canada approved, Theralase has been focusing on recruiting a high performing sales and marketing team in Canada and the US with the mandate of dramatically increasing sales of the TLC-2000 across Canada and the United States, in 2016. Once these strategic markets have been established and running independently, Theralase will focus on growing its international revenues through exclusive international distribution agreements, in 2017.

Cost of sales for the six-month period ended June 30, 2016 was $281,288 (31% of revenue) resulting in a gross margin of $611,850 or 69% of revenue, compared to a cost of sales of $243,394 (36% of revenue) in 2015, resulting in a gross margin of $434,423 or 64% of revenue. Cost of sales is represented by the following costs: raw materials, subcontracting, direct and indirect labour and the applicable share of manufacturing overhead. As revenues increase, volume purchasing will continue to reduce the cost of goods sold.

Selling and marketing expenses for the six-month period ended June 30, 2016 were $665,727 representing 75% of sales, compared with $402,598 or 59% in 2015. The increase is primarily due to increased spending in marketing and sales personnel, which will augment sales in future financial quarters, aiding in sales of the TLC-2000. Selling expenses are expected to continue to increase in the future as the Company expands in Canada, the US and international markets. On-going investment in sales personnel, marketing events and advertising are necessary expenses to generate and increase revenues in subsequent financial quarters. As revenues increase, selling and marketing expenses will decrease as a percentage of revenues.

Administrative expenses for the six-month period ended June 30, 2016 were $1,407,950 representing a 43% increase from $982,841 in 2015. Increases in administrative expenses are attributed to the following:

General and administrative expenses increased 44% due to increased spending on investor relations and research scientist activities
Stock based compensation increased by 134% as a result of vesting of stock options to certain employees, directors and officers of the Company in 2Q2016
Administrative salaries increased by 49% as a result of hiring clinical and educational staff.

Gross research and development expenses totaled $925,581 for the six-month period ended June 30, 2016 compared to $1,356,664 in 2015 (32% decrease). Research and development expenses represented 31% of the Company’s operating expenses for the period and represent direct investment into the research and development expenses of the TLC-3000 anti-cancer technology.

The net loss for the six-month period ended June 30, 2016 was $2,390,119, which included $422,730 of net non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss and lease inducements). This compared to a net loss for the same period in 2015 of $2,279,117, which included $197,152 of net non-cash expenses. The PDT division represented $1,670,064 of this loss (70%). The increase in net loss is due to increased investment in research and development of the TLC-3000, sales, marketing and administrative personnel, all related to the commencement of a Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer (“NMIBC”) and sales of the next generation TLC-2000 therapeutic medical laser system, respectively.

Theralase has been very successful in executing on its strategic objectives in 2015 and 2H2016 by completing:

Health Canada Medical Device Licence (Class III) approval of its next generation TLC-2000 Therapeutic Medical Laser System
US Food and Drug Administration (“FDA”) 510(k) clearance of the TLC-2000
Health Canada Clinical Trial Application (“CTA”) approval
Princess Margaret Cancer Centre, University Health Network (“UHN”) Research Ethics Board (“REB”) approval
Demonstrated 6 month accelerated stability and 9 month long term stability of it lead anti-cancer PDC TLD-1433
Signed a Clinical Research Agreement (“CRA”) with UHN to conduct a Phase Ib clinical study for the indication of NMIBC.

Theralase has completed sterilization, biocompatibility and mechanical testing of the TLC-3400 Dosimetry Fibre Optic Cage (“DFOC”) medical laser probes, to be used in conjunction with the TLC-3200 Medical Laser System, to activate TLD-1433 that has absorbed into bladder cancer lesions and has submitted the information to Health Canada, via an Investigational Testing Authorization (“ITA”) on July 29, 2016.

Health Canada required information and testing that supported:

Biocompatibility (the materials that enter the body are proven not harmful to tissue)
Mechanical testing (the materials demonstrate the characteristics of functional reliability, tensile strength and repeatability of operation)
Sterility (the materials that enter the body are demonstrated to be sterile)

Pending Health Canada approval of the ITA, expected in September 2016, Theralase will immediately commence enrollment of patients into a Phase Ib clinical study in the treatment of NMIBC. The primary outcome measures of the Phase Ib clinical study will be safety and tolerability, with a secondary outcome measure of pharmacokinetics (where the drug accumulates in tissue and how it exits the body) and an exploratory outcome measure of efficacy.

The Phase Ib NMIBC clinical study protocol will commence by instilling a low dose of TLD-1433 drug into the bladders of three (3) patients with subsequent light activation using the TLC-3200 / TLC-3400 medical laser technology. These three (3) patients will then be monitored for thirty (30) days to ensure safety and tolerability of the procedure. If no adverse events are reported, then an additional six (6) patients will be enrolled at a high dose, followed by light activation and follow-up monitoring for six (6) months.

If safety and tolerability of the procedure is demonstrated in these nine (9) patients, the Phase Ib study results will support Health Canada approval and a Phase IIb multi-center efficacy study for NMIBC will be commenced in Canada, the United States and Europe.

Mr. Dumoulin-White concluded that, “The Company looks forward to final approval of the ITA by Health Canada, allowing the Company to commence a Phase Ib clinical study for NMIBC. This will allow the Company to dramatically increase shareholder value in 4Q2016 by demonstrating the safety, tolerability and as an exploratory outcome measure efficacy of its next generation anti-cancer technology.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 444493

TORONTO, ON / ACCESSWIRE / August 29, 2016 / (TSX Venture Exchange: BCC)

The Canadian Bioceutical Corporation (“BCC” or the “Company”) announces today its financial results for the interim quarter ended June 30, 2016. Financial Statements and the related MD&A are available under BCC’s corporate profile at www.sedar.com.

The Company is continuing with its negotations, documentation and financing efforts in respect of the possible acquisition announced earlier this year and will provide the market with updates as the project moves closer to conclusion.

As well, BCC continues with efforts to secure a medical marijuana license under Canada’s Marijuana for Medical Purposes Regulations by responding to recent clarification requests from Health Canada.

About The Canadian Bioceutical Corporation

BCC, formerly Allegiance Equity Corporation, is an Ontario corporation that, for over two decades has been developing unique standardized mass-market nutraceutical products for the treatment of common ailments where present pharmaceutical treatments and over-the-counter products fail to meet the needs of patients. BCC has targeted markets having clearly identified product deficiencies and dissatisfied consumers afflicted with a variety of medical conditions. BCC obtains regulatory approval and patents for these unique compounds and formulations and may produce and distribute or license its products for royalty revenues.

BCC’s principal brands are CinG-X™, ReliévaTM, and Psorberine™ and FertaMaxTM. Additionally BCC, through its wholly-owned subsidiary BioCannabis Products Ltd. and, subsequent to receiving its MMPR license from Health Canada and as part of its planned expansion into the U.S. medical marijuana sector, intends to develop and market a series of new cannabis-based branded medicinal products to address this rapidly-evolving market.

Investors should be aware that companies cannot legally conduct a medical marijuana business in Canada without a license from Health Canada and that there is significant time and cost required to obtain such a license. As a publicly-traded company publicizing its intention to enter the medical marijuana industry, BCC urges potential investors in any company in this sector, to become familiar with the required resources and the related risks, costs implications and time required before a company will be able to begin licensed operations. There is no assurance that any company announcing its intent to enter the medical marijuana industry will be successful in obtaining a license or in creating shareholder value.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and BCC’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in BCC’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although BCC believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, BCC disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the Policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release.

For further information please contact:

Scott Boyes, President and CEO, The Canadian Bioceutical Corporation
scott@canadianbioceutical.com
(416) 840-4703

SOURCE: The Canadian Bioceutical Corporation

ReleaseID: 444494

TORONTO, ON AND NEW YORK, NY / ACCESSWIRE / August 29, 2016 / Intertainment Media Inc. (TSXV: INT) (OTC Pink: ITMTF) (FSE: I4T) (“Intertainment” or the “Company”) is pleased to announce the results of its Annual General and Special Meeting of shareholders held on August 29, 2016.

All matters submitted to shareholders, including the election of Messers Wayne Parson, Joel Strickland and Douglas Hamilton as directors, were approved, other than the proposed consolidation of the Company’s common shares on a 10 for 1 basis, previously announced on August 4, 2016 (the “Proposed Consolidation”), which was rejected by shareholders.

The intended purpose of the Proposed Consolidation was to provide a more attractive capital structure in order to seek additional financing for the Company. Says Wayne Parsons, Chief Executive Officer, “Management is disappointed with this result and will re-assess its go-forward plans for the Company.”

The Company currently has 37,988,877 common shares issued and outstanding.

Contact:

For further information on the Company please contact:

info@intertainmentmedia.com

Forward Looking Information

This news release contains certain “forward-looking information” within the meaning of such statements under applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Actual timelines associated may vary from those anticipated in this news release and such variations may be material. Actual results could differ materially because of factors discussed in the management discussion and analysis section of our interim and most recent annual financial statements or other reports and filings with the TSX Venture Exchange Inc. (TSXV) and applicable Canadian securities regulators. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on this forward-looking information.

The TSXV has in no way passed upon the merits of the Proposed Consolidation and has neither approved nor disapproved the contents of this press release.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Intertainment Media Inc.

ReleaseID: 444492

TORONTO, ON / ACCESSWIRE / August 29, 2016 / Gunpowder Capital Corp., (CSE: GPC) (FSE: YS6N) (the “Corporation”) announced today that it has closed the second tranche of its non-brokered private placement raise which was announced on July 4th, 2016. In total, One Hundred Thousand Dollars (“$100,000.00”) CDN was raised via the sale of Ten Thousand (“10,000”) Series “A” Preferred Shares at $10.00 per share. No commission or finder’s fee is payable with respect to the closing of this tranche of the placement. To date, the Corporation has raised in total One Hundred and Sixty Five Thousand Dollars & Five hundred Dollars (“$165,500.00”) CDN in this offering. The Corporation is extending the closing date of this offering to Oct 14th, 2016.

The Corporation also announced today the voting results from AGM meeting of the shareholders held on August 24th, 2016. Shareholders voted in favour of all items of business. In total 7,821,045 shares were voted at the AGM representing 31% of the outstanding total with the following results:

Election of Steve Mlot as Director
95% in favor for | 5% withheld

Election of Frank Kordy as Director
94% in favor for | 6% withheld

Election of Dan Collia as Director
88% in favor for | 12% withheld

Appointment of Ross Pope LLP., as the Auditors of the Corporation
100% in favor for | 0% against

Approval of the Corporation’s Stock Option Plan
88% in favor for | 12% against

Mr. Frank Kordy stated: “We are very pleased to see that we’ve received strong support from our shareholders at the AGM in continuing our business mandate. We continue our business strategy of entering into deals and acquiring assets that are revenue generating.”

For further information please contact:

Mr. Frank Kordy
Interim CEO & Director
Gunpowder Capital Corp.
T: (647) 466-4037
E: frank.kordy@gunpowdercapitalcorp.com

Mr. Paul Haber
CFO
Gunpowder Capital Corp.
T: (416) 363-3833
E: paul.haber@gunpowdercapitalcorp.com

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Gunpowder Capital Corp.

ReleaseID: 444489

VANCOUVER, BC / ACCESSWIRE / August 29, 2016 / Prophecy Development Corp. (“Prophecy” or the “Company”) (TSX:PCY, OTC:PRPCD, Frankfurt:1P2N) is pleased to report that the non-brokered private placement of 150,000 units for $570,000 previously announced on August 8, 2016 was oversubscribed. As a result, the Company closed today the private placement of 202,735 units (each a “Unit”) at a price of $3.80 per Unit for gross proceeds of $770,393 (the “Placement”). Each Unit consists of one Common share in the capital of the Company (a “Share”) and one half of one Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire an additional Share at a price of $4.40 per Share for a period of five years from the date of issuance.

The Warrants will be subject to the following acceleration conditions:

in the event that the closing price of the Shares trading on the Toronto Stock Exchange (the “TSX”) exceeds $8.80 per Common Share; or
the closing spot price of silver as quoted by KITCO Metals Inc. exceeds USD$28.00 per ounce,

in either instance, for a period of over 28 consecutive calendar days, at Prophecy’s election, the exercise period may be reduced in which case, Warrant holders will only be entitled to exercise their Warrants for a period of 30 days from the date the Company either disseminates a press release or sends written notice to the Warrant holders advising them of the reduced and accelerated exercise period after which, the Warrants will expire.

The Shares will be subject to a minimum hold period of four months plus one day from the date of issue.

The Company paid in cash, total finder’s fees of $3,464.65 in connection with the Placement.

Proceeds of the Placement are expected to be used to develop Prophecy’s mineral projects and for general working capital purposes.

The Company also announces that John Lee, of Suite 1301, 12 Harcourt Road, Central, Hong Kong, Executive Chairman of the Company, acquired 60,000 Units pursuant to the Placement for total consideration of $228,000.

Prior to the Placement, Mr. Lee beneficially owned 1,009,953 Shares, representing approximately 22.16% of the issued and outstanding shares of the Company. In addition, Mr. Lee holds 137,873 incentive stock options, each entitling him to acquire one Share.

As a result of the Placement, Mr. Lee now beneficially owns and exercises control over an aggregate of 1,069,953 Shares representing an interest of approximately 22.47% of the Company’s currently issued and outstanding Shares, 22.96% of the Company’s Shares on a partially diluted basis assuming full exercise of only the 30,000 Warrants attached to Mr. Lee’s 60,000 Placement Units, and 34.33% of the Company’s Shares on a fully diluted basis assuming exercise of all of the Company’s outstanding share purchase warrants.

The 60,000 Placement Units were acquired by Mr. Lee for investment purposes only, and not for purposes of exercising control or direction over the Company.

Generally, Mr. Lee intends to evaluate his investment in the Company and to increase or decrease his shareholdings as circumstances require, depending on market conditions and other factors, through market transactions, private agreements or otherwise.

The information contained in this news release regarding Mr. Lee’s early warning report has been provided by Mr. Lee and the Company is not responsible for its accuracy.

A copy of the early warning report pursuant to National Instrument 62-103 required to be filed with the applicable securities commissions in connection with the acquisition of the Units described in this news release will be available for viewing under the Company’s profile at www.sedar.com. A copy of the early warning report can also be obtained from the contact number for Investor Relations below.

About Prophecy

Prophecy Development Corp. is a Canadian public company listed on the Toronto Stock Exchange that is engaged in developing mining and energy projects in Mongolia, Bolivia and Canada. Further information on Prophecy can be found at www.prophecydev.com.

PROPHECY DEVELOPMENT CORP.

ON BEHALF OF THE BOARD

“JOHN LEE”

Executive Chairman

For more information about Prophecy, please contact Investor Relations:
+1.888.513.6286
ir@prophecydev.com
www.prophecydev.com

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this news release, including statements which may contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, or similar expressions, and statements related to matters which are not historical facts, are forward-looking information within the meaning of applicable securities laws. Such forward-looking statements, which reflect management’s expectations regarding Prophecy’s future growth, results of operations, performance, business prospects and opportunities, are based on certain factors and assumptions and involve known and unknown risks and uncertainties which may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements.

These factors should be considered carefully, and readers should not place undue reliance on the Prophecy’s forward-looking statements. Prophecy believes that the expectations reflected in the forward-looking statements contained in this news release and the documents incorporated by reference herein are reasonable, but no assurance can be given that these expectations will prove to be correct. In addition, although Prophecy has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Prophecy undertakes no obligation to release publicly any future revisions to forward-looking statements to reflect events or circumstances after the date of this news or to reflect the occurrence of unanticipated events, except as expressly required by law.

SOURCE: Prophecy Development Corp.

ReleaseID: 444487

NEW YORK, NY / ACCESSWIRE / August 29, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Rackspace Hosting, Inc. (“Rackspace Hosting”) (NYSE: RAX) stock prior to August 26, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Rackspace Hosting to Apollo Global Management LLC. Under the terms of the transaction, Rackspace shareholders will receive $32.00 for each share of Rackspace stock they own. To learn more about the action and your rights, go to: http://zlk.9nl.com/rackspace-hosting-rax or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 444485